Ring Therapeutics was founded by Flagship Pioneering in 2017 with the goal of developing a commensal virome platform for use in gene therapies. The company has developed an anellovirus database with thousands of newly discovered anello-based vector candidates.

Ring has also built a platform to harness the unique properties of commensal anelloviruses to generate an array of vectors with tissue-specific tropism and the ability to potentially be redosed. The anellovirus vectors carry circular, single-stranded DNA molecules that do not integrate with human DNA, thereby overcoming a key limitation of current viral gene therapy approaches. Ring's vector platform is fully integrated for the discovery and vectorization of anelloviruses to produce programmable medicines.

The series B financing round included contributions by Invus, Altitude Life Science Ventures, Partners Investment, and UPMC Enterprises, as well as funds and accounts advised by T. Rowe Price Associates.

Senda accelerates drug development platform with $98M in new funding
Senda Biosciences announced it has closed $98 million in financing to bring the company's platform and its therapeutic programs into clinical trials.

Flagship Pioneering unveils eRNA platform from Laronde
Flagship Pioneering unveiled its Laronde platform for the development of endless RNA (eRNA), a novel, engineered form of RNA that can be programmed to...

Repertoire Immune Medicines secures $189M
Repertoire Immune Medicines has completed a round of financing, raising $189 million to further expand its Decode discovery platform, accelerate...

Tessera closes $230M in series B round for gene writing tech
Tessera Therapeutics has raised over $230 million in series B financing to advance its gene writing technology, capable of writing therapeutic instructions...